212 related articles for article (PubMed ID: 26577335)
21. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
Owen CE
Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
[TBL] [Abstract][Full Text] [Related]
22. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
Novosad J; Krčmová I
Int J Immunopathol Pharmacol; 2020; 34():2058738420942386. PubMed ID: 32689848
[TBL] [Abstract][Full Text] [Related]
23. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
24. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
25. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
Dodig S; Richter D; Cepelak I; Benko B
Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
[TBL] [Abstract][Full Text] [Related]
26. [Pratical aspects of anti-Ige therapy in severe allergic asthma].
Taramarcaz P; Hauser C; Rochat T
Rev Med Suisse; 2007 Apr; 3(108):1050-2, 1054-5. PubMed ID: 17552257
[TBL] [Abstract][Full Text] [Related]
27. Targeting IgE in asthma.
Kuhl K; Hanania NA
Curr Opin Pulm Med; 2012 Jan; 18(1):1-5. PubMed ID: 22139745
[TBL] [Abstract][Full Text] [Related]
28. Does anti-IgE therapy help in asthma? Efficacy and controversies.
Avila PC
Annu Rev Med; 2007; 58():185-203. PubMed ID: 17059361
[TBL] [Abstract][Full Text] [Related]
29. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
31. Anti-IgE in severe persistent allergic asthma.
Fox H
Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
[TBL] [Abstract][Full Text] [Related]
32. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
34. From IgE to Omalizumab.
Kawakami T; Blank U
J Immunol; 2016 Dec; 197(11):4187-4192. PubMed ID: 27864548
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
36. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
[No Abstract] [Full Text] [Related]
37. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
38. Development of assay for determining free IgE levels in serum from patients treated with omalizumab.
Ito R; Gon Y; Nunomura S; Atsuta R; Harada N; Hattori T; Maruoka S; Okayama Y; Ra C; Hashimoto S
Allergol Int; 2014 May; 63 Suppl 1():37-47. PubMed ID: 24809374
[TBL] [Abstract][Full Text] [Related]
39. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
[No Abstract] [Full Text] [Related]
40. Pediatric use of omalizumab for allergic asthma.
Pajno GB; Castagnoli R; Arasi S; Licari A; Caminiti L; Marseglia GL
Expert Opin Biol Ther; 2020 Jul; 20(7):695-703. PubMed ID: 32241196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
